CA2587936A1 - Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine - Google Patents

Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine Download PDF

Info

Publication number
CA2587936A1
CA2587936A1 CA002587936A CA2587936A CA2587936A1 CA 2587936 A1 CA2587936 A1 CA 2587936A1 CA 002587936 A CA002587936 A CA 002587936A CA 2587936 A CA2587936 A CA 2587936A CA 2587936 A1 CA2587936 A1 CA 2587936A1
Authority
CA
Canada
Prior art keywords
hydrogen
compound
alkyl
tetrahydropyridin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002587936A
Other languages
English (en)
Inventor
Roelof Van Hes
Pieter Smid
Cornelis G. Kruse
Martinus Th. M. Tulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Healthcare Products BV
Original Assignee
Solvay Pharmaceuticals B.V.
Roelof Van Hes
Pieter Smid
Cornelis G. Kruse
Martinus Th. M. Tulp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V., Roelof Van Hes, Pieter Smid, Cornelis G. Kruse, Martinus Th. M. Tulp filed Critical Solvay Pharmaceuticals B.V.
Publication of CA2587936A1 publication Critical patent/CA2587936A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA002587936A 2004-12-07 2005-12-06 Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine Abandoned CA2587936A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US63343904P 2004-12-07 2004-12-07
EP04106351.2 2004-12-07
US60/633,439 2004-12-07
EP04106351 2004-12-07
PCT/EP2005/056501 WO2006061373A2 (fr) 2004-12-07 2005-12-06 Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine

Publications (1)

Publication Number Publication Date
CA2587936A1 true CA2587936A1 (fr) 2006-06-15

Family

ID=34930005

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002587936A Abandoned CA2587936A1 (fr) 2004-12-07 2005-12-06 Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine

Country Status (14)

Country Link
EP (1) EP1828168A2 (fr)
JP (1) JP2008523027A (fr)
KR (1) KR20070091009A (fr)
CN (1) CN101072770A (fr)
AR (1) AR052146A1 (fr)
AU (1) AU2005313387A1 (fr)
BR (1) BRPI0518465A2 (fr)
CA (1) CA2587936A1 (fr)
MX (1) MX2007006757A (fr)
RU (1) RU2007125692A (fr)
SA (1) SA05260388B1 (fr)
TW (1) TW200626575A (fr)
WO (1) WO2006061373A2 (fr)
ZA (1) ZA200704155B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2249649A4 (fr) * 2008-02-05 2012-09-26 Watson Pharma Private Ltd Procédé amélioré pour la préparation de palipéridone

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8900382D0 (en) * 1989-01-09 1989-03-08 Janssen Pharmaceutica Nv 2-aminopyrimidinone derivatives
EP1200072A2 (fr) * 1999-05-12 2002-05-02 Solvay Pharmaceuticals B.V. Methode de traitement de troubles psychotiques
AU2003257407A1 (en) * 2002-08-29 2004-03-19 H. Lundbeck A/S S-(+)-3-{1-(2-(2,3-dihydro-1h-indol-3-yl)ethyl)-3,6-dihydro-2h-pyridin-4-yl}-6-chloro-1h-indole and acid addition salts thereof

Also Published As

Publication number Publication date
SA05260388B1 (ar) 2009-06-09
RU2007125692A (ru) 2009-01-20
WO2006061373A2 (fr) 2006-06-15
JP2008523027A (ja) 2008-07-03
AU2005313387A1 (en) 2006-06-15
TW200626575A (en) 2006-08-01
WO2006061373A3 (fr) 2006-09-21
EP1828168A2 (fr) 2007-09-05
ZA200704155B (en) 2008-08-27
AR052146A1 (es) 2007-03-07
CN101072770A (zh) 2007-11-14
KR20070091009A (ko) 2007-09-06
BRPI0518465A2 (pt) 2008-11-18
MX2007006757A (es) 2007-11-09

Similar Documents

Publication Publication Date Title
US5834493A (en) Indole derivatives as 5-HT1A and/or 5-HT2 ligands
NZ539390A (en) Azaindole derivatives as inhibitors of p38 kinase
HUT70195A (en) Process for producing benzimidazolone derivatives and pharmaceutical preparations containing them
AU2005313312A1 (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition
SK287018B6 (sk) Deriváty fenylpiperazínov, spôsob ich prípravy, farmaceutická kompozícia s ich obsahom a ich použitie
JPH06145170A (ja) ヘテロ環式化合物、その製法及びこれを含有する高血圧及びうつ血性心不全治療用医薬組成物
EP0470039A2 (fr) Dérivés de 3-arylindole et 3-arylindazole
US20050209228A1 (en) 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site
ZA200704156B (en) Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
CA2093433C (fr) Promedicaments produits par le sertindole
JP2004509873A (ja) セロトニン受容体及びドーパミン受容体にアフィニティーを示す新規ｎ，ｎ’−二置換ベンゾイミダゾロン誘導体
AU2005313386A1 (en) Phenylpiperazines with a combination of affinity for dopamine -D2 receptors and serotonin reuptake sites
JPH05221989A (ja) 複素環式化合物
IL142589A (en) 3 - Tetrahydropyridine - 4 Indulators and pharmaceuticals containing them
CA2587936A1 (fr) Indoles de tetrahydropyridine-4-yle comportant une combinaison de sites a affinite avec des recepteurs de dopamine d2 et inhibant la reabsorption de la serotonine
US7371769B2 (en) Tetrahydropyridin-4-yl indoles with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20060122175A1 (en) Benzdioxane piperazine derivatives with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
FR2761070A1 (fr) Derives de dihydropyrazino[1,2-a]indole-1-one, leur preparation et leur application en therapeutique
MX2007006818A (es) Derivados de fenilpiperazina con una combinacion de agonismo parcial del receptor de dopamina-d2 e inhibicion de la reabsorcion de serotonina.
US20060122177A1 (en) Phenylpiperazines with a combination of affinity for dopamine-D2 receptors and serotonin reuptake sites
US20060247256A1 (en) Phenylpiperazine derivatives with a combination of partial dopamine-D2 receptor agonism and serotonin reuptake inhibition

Legal Events

Date Code Title Description
FZDE Discontinued